Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Files An 8-K Other Events
Item 8.01
|
Other Events. |
On December22, 2016, Synergy Pharmaceuticals Inc. (the Company)
issued a press release announcing positive top-line results from
the second of two pivotal phase 3 clinical trials evaluating the
efficacy and safety of plecanatide, an investigational once-daily
orally-administered compound, in 1,054 adult patients with
irritable bowel syndrome with constipation (IBS-C).
The press release is attached as Exhibit99.1 to this report on
Form8-K and is incorporated herein by reference.
|
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
99.1 Synergy Pharmaceuticals Inc. Press Release dated December22,
2016.
About Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company’s uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Recent Trading Information
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) closed its last trading session up +1.03 at 5.77 with 32,385,621 shares trading hands.
